In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3250-3260

  Zhou, Yabin ^a   Wang, Ganggang ^a   Li, Yutang ^a   Liu, Yang ^a   Song, Yu ^a   Zheng, Wenshuai ^a   Zhang, Ning ^a   Hu, Xiaoyan ^a   Yan, Shikun ^a   Jia, Jihui ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMPHOTERICIN B;

ARTICLE; BIOFILM; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PLANKTON; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPIRIN; BIOFILMS; CANDIDA ALBICANS; MICROBIAL SENSITIVITY TESTS;

EID: 84861175951     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06082-11     Document Type: Article

References (49)

1. Afeltra J, Vitale RG, Mouton JW, Verweij PE. 2004. Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob. Agents Chemother. 48:1335-1343. (Pubitemid 38405490)
2. Al-Bakri AG, Othman G, Bustanji Y. 2009. the assessment of the antibacterial and antifungal activities of aspirin, EDTA, and an aspirin-EDTA combination and their effectiveness as antibiofilm agents. J. Appl. Microbiol. 107:280 -286.
3. Alem MA, Douglas LJ. 2004. Effects of aspirin and other nonsteroidal anti-inflammatory drugs on biofilms and planktonic cells of Candida albicans. Antimicrob. Agents Chemother. 48:41-47. (Pubitemid 38040174)
4. Alem MA, Douglas LJ. 2005. Prostaglandin production during growth of Candida albicans biofilms. J. Med. Microbiol. 54:1001-1005. (Pubitemid 41566768)
5. Al-Fattani MA, Douglas LJ. 2006. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J. Med. Microbiol. 55:999-1008. (Pubitemid 44215557)
6. Chapman SW, Sullivan DC, Cleary JD. 2008. In search of the holy grail of antifungal therapy. Trans. Am. Clin. Climatol. Assoc. 119:197-216.
7. Cowen LE, Steinbach WJ. 2008. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot. Cell 7:747-764. (Pubitemid 351968819)
8. Kuhn DM, Balkis M, Chandra J, Mukherjee PK, Ghannoum MA. 2003. Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J. Clin. Microbiol. 41:506-508. (Pubitemid 36098635)
9. d'Enfert C. 2006. Biofilms and their role in the resistance of pathogenic Candida to antifungal agents. Curr. Drug Targets 7:465-470. (Pubitemid 43744837)
10. Da Silva WJ, et al. 2008. Improvement of XTT assay performance for studies involving Candida albicans biofilms. Braz. Dent. J. 19:364-369.
11. Deva R, Ciccoli R, Kock L, Nigam S. 2001. Involvement of aspirinsensitive oxylipins in vulvovaginal candidiasis. FEMS Microbiol. Lett. 198: 37-43. (Pubitemid 32452238)
12. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15:167-193. (Pubitemid 34303762)
13. Ernst EJ, Klepser ME, Pfaller MA. 1998. In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: effect of concentration and exposure time. Diagn. Microbiol. Infect. Dis. 32:205-210. (Pubitemid 29017740)
14. Ernst EJ, Roling EE, Petzold CR, Keele DJ, Klepser ME. 2002. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother. 46:3846-3853. (Pubitemid 35403260)
15. Finkel JS, Mitchell AP. 2011. Genetic control of Candida albicans biofilm development. Nat. Rev. Microbiol. 9:109-118.
16. Garcia-Sańchez S, et al. 2004. Candida albicans biofilms: a developmental state associated with specific and stable gene expression patterns. Eukaryot. Cell 3:536-545. (Pubitemid 38497991)
17. Gilbert P, Maira-Litran T, McBain AJ, Rickard AH, Whyte FW. 2002. The physiology and collective recalcitrance of microbial biofilm communities. Adv. Microb. Physiol. 46:203-256. (Pubitemid 34602243)
18. Govindsamy V, Rossignol T, d'Enfert C. 2010. Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to β-glucans. Antimicrob. Agents Chemother. 54: 2096-2111.
19. Granger BL, Flenniken ML, Davis DA, Mitchell AP, Cutler JE. 2005. Yeast wall protein 1 of Candida albicans. Microbiology 151:1631-1644. (Pubitemid 40711808)
20. Jin Y, Samaranayake LP, Samaranayake Y, Yip HK. 2004. Biofilm formation of Candida albicans is variably affected by saliva and dietary sugars. Arch. Oral Biol. 49:789-798. (Pubitemid 39081809)
21. Johnson RH, Einstein HE. 2007. Amphotericin B and coccidioidomicosis. Ann. N. Y. Acad. Sci. 1111:434-441.
22. Laniado-Laborín R, Cabrales-Vargas MN. 2009. Amphotericin B: side effects and toxicity. Rev. Iberoam. Micol. 26:223-227.
23. Mazur I, et al. 2007. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-κB-inhibiting activity. Cell Microbiol. 9:1683-1694. (Pubitemid 46958795)
24. Meletiadis J, Mouton JW, Meis JFGM, Verweij PE. 2003. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother. 47:106-117. (Pubitemid 36070350)
25. Meletiadis J, et al. 2001. Comparison of spectrophotometric and visual reading of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5- [(sulfenylamino) carbonyl]-2H-tetrazolium hydroxide], for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:4256-4263. (Pubitemid 33117107)
26. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. 2005. Combination treatment of invasive fungal infections. Clin. Microbiol. Rev. 18:163-194. (Pubitemid 40170667)
27. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. 2003. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect. Immun. 71:4333-4340. (Pubitemid 36919897)
28. Nett J, et al. 2007. Putative role of β-1,3 glucans in Candida albicans biofilm resistance. Antimicrob. Agents Chemother. 51:510-520. (Pubitemid 46185268)
29. Nobile CJ, et al. 2006. Critical role of Bcr1-dependent adhesins in Candida albicans biofilm formation in vitro and in vivo. PLoS Pathog. 2:e63.
30. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. Document M27-A2. NCCLS, Wayne, PA.
31. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1. (Pubitemid 36850074)
32. Pina-Vaz C, et al. 2000. Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species. J. Med. Microbiol. 49:831-840. (Pubitemid 30666636)
33. Polak A. 1999. The past, present and future of antimycotic combination therapy. Mycoses 42:355-370. (Pubitemid 29457850)
34. Ramage G, Martinez JP, Lopez-Ribot JL. 2006. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res. 6:979-986. (Pubitemid 44568854)
35. Ramage G, VandeWalle K, Wickes BL, Lopez-Ribot JL. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479. (Pubitemid 32801898)
36. Robbins N, et al. 2011. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog. 7:e1002257. doi:10.1371/journal.ppat.1002257.
37. Sanglard D, Odds FC. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85. (Pubitemid 36114141)
38. Schuck EL, Derendorf H. 2005. Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev. Anti-Infect. Ther. 3:361-373. (Pubitemid 40872531)
39. Scott EM, Tariq VN, McCrory RM. 1995. Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. Antimicrob. Agents Chemother. 39: 2610-2614.
40. Sun, et al. 2008. In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods. Antimicrob. Agents Chemother. 52:409-417. (Pubitemid 351170807)
41. Stepanovic S, Vukovic D, Jesic M, Ranin L. 2004. Influence of acetylsalicylic acid (aspirin) on biofilm production by Candida species. J. Chemother. 16:134-138. (Pubitemid 38756944)
42. Stewart P, Costerton J. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138. (Pubitemid 32709857)
43. Taha MO, Al-Bakri AG, Zalloum WA. 2006. Discovery of potent inhibitors of pseudomonal quorum sensing via pharmacophore modeling and in silico screening. Bioorg. Med. Chem. Lett. 16:5902-5906. (Pubitemid 44486725)
44. Te Dorsthorst DT, et al. 2002. In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob. Agents Chemother. 46:2982-2989.
45. Trofa D, Gacser A, Nosanchuk JD. 2008. Candida parapsilosis, an emerging fungal pathogen. Clin. Microbiol. Rev. 21:606-625.
46. Trofa D, et al. 2009. Acetylsalicylic acid (aspirin) reduces damage to reconstituted human tissues infected with Candida species by inhibiting extracellular fungal lipases. Microbes Infect. 11:1131-1139.
47. Wang W, et al. 2003. Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut 52:490-495. (Pubitemid 36363398)
48. Wu KK. 2000. Aspirin and salicylate: an old remedy with a new twist. Circulation 102:2022-2023.
49. Zhao X, et al. 2006. Candida albicans Als3p is required for wild-type biofilm formation on silicone elastomer surfaces. Microbiology 152:2287-2299. (Pubitemid 44219638)